Skip to main content
Signal8

EULAR 2026: Dapirolizumab Pegol Shows Potential to Reduce Flare Rates and Maintain Disease Control in Systemic Lupus Erythematosus

$BIIBPress releaseJun 4, 2026, 1:00 AM ETRead the release

Biogen and partner UCB presented additional Phase 3 data for dapirolizumab pegol at the EULAR 2026 Congress, showing sustained disease control with reduced steroid exposure in systemic lupus erythematosus patients. Post-hoc analyses from the PHOENYCS GO study indicated that patients on dapirolizumab pegol were more likely to maintain disease control while tapering glucocorticoids to ≤7.5 mg/day through Week 48 compared to placebo.

Key figures

Drug Name
dapirolizumab pegol
Phase Of Trial
Phase 3
Study name
PHOENYCS GO
Duration weeks
48
Glucocorticoid taper threshold mg
7.5

AI analysis

The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.

    BIIB: EULAR 2026: Dapirolizumab Pegol Shows Potential to Reduce Flare Rates and Maintain Disease Control in Systemic Lupus Erythematosus — AI Analysis | Signal8